{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:57:36Z","timestamp":1784159856986,"version":"3.55.0"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013739","name":"Pfizer","doi-asserted-by":"publisher","award":["68718373"],"award-info":[{"award-number":["68718373"]}],"id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Purpose: Timeliness of systemic therapy initiation for advanced lung cancer is highly dependent on pathology and molecular pathology laboratory services. Here, we aimed to prospectively evaluate liquid biopsy as a potential strategy to expedite systemic therapy decision-making in lung cancer management. Patients and Methods: This prospective cohort study included consecutive patients with suspected lung cancer seen at the time of initial specialist consultation who underwent both liquid and solid tumour biopsy (group A) and patients with confirmed lung malignancy who underwent solid tumour biopsy alone (group B), between 1 February 2022 and 31 May 2023. Due to laboratory factors, liquid biopsies were processed in batches of 13, whereas solid tumour biopsies were processed individually upon receipt, as per standard practices. Co-primary endpoints included the time from solid versus liquid biopsies to biomarker reporting and palliative systemic therapy initiation. Results: A total of 324 patients were included in the study. The median time from date of blood draw to date of liquid biopsy result was 78 days. For group A (n = 50), the median time from date of solid tumour biopsy to biomarker reporting was 22 days, and the median time from date of solid tumour biopsy to palliative systemic therapy was 42 days. The median time from date of liquid biopsy blood draw to palliative systemic therapy initiation was 56 days. For group B (n = 274), the median times from date of biopsy to biomarker reporting and to palliative systemic therapy initiation in all patients were 22 and 47 days, respectively. Conclusions: While we did not demonstrate improvement in timeliness of biomarker reporting or systemic therapy initiation with liquid biopsy, several barriers leading to delay in liquid biopsy reporting were identified due to unexpected COVID-19-related supply chain disruption and the cost-limiting need to batch sample analysis. Further studies that address the identified barriers are warranted to assess the potential improvement in timeliness of care, should liquid biopsy analysis be implemented in real-time.<\/jats:p>","DOI":"10.3390\/curroncol33010042","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:13:51Z","timestamp":1768299231000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Utility and Implementation Barriers of a Liquid Biopsy Biomarker Test Early in the Lung Cancer Diagnostic Pathway to Improve Timeliness of Palliative Systemic Therapy"],"prefix":"10.3390","volume":"33","author":[{"given":"Adi","family":"Kartolo","sequence":"first","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"Escarpment Cancer Research Institute, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8244-7426","authenticated-orcid":false,"given":"Laura","family":"Semenuk","sequence":"additional","affiliation":[{"name":"Molecular Genetics Laboratory, Kingston Health Sciences Centre, Kingston, ON K7L 2V7, Canada"},{"name":"Department of Pathology and Molecular Medicine, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1388-2183","authenticated-orcid":false,"given":"Harriet","family":"Feilotter","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 3K3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8107-7648","authenticated-orcid":false,"given":"Colleen","family":"Savage","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"},{"name":"Vice-Principal Research Office, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Boag","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3023-0080","authenticated-orcid":false,"given":"Wilma","family":"Hopman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1858-0387","authenticated-orcid":false,"given":"Genevi\u00e8ve","family":"Digby","sequence":"additional","affiliation":[{"name":"Division of Respirology and Sleep Medicine, Department of Medicine, Queen\u2019s University, Kingston, ON K7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Mates","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1200\/JCO-25-01061","article-title":"Theerapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, versin 2025.1","volume":"43","author":"Reuss","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_2","unstructured":"(2025, December 24). National Comprehensive Cancer Network Guidelines. Non-Small Cell Lung Cancer. Version 3.2026. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.21037\/tlcr-19-675","article-title":"Impact of time-to-treatment on overall survival of non-small cell lung cancer patients\u2014An analysis of the national cancer database","volume":"9","author":"Anggondowati","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thoraxjnl-2021-216865","article-title":"Association between time-to-treatment and outcomes in non-small cell lung cancer: A systematic review","volume":"77","author":"Hall","year":"2022","journal-title":"Thorax"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jtho.2016.05.001","article-title":"Detection and monitoring of the BRAF mutation in circulating tumor cells and circulating tumor DNA in BRAF-mutated lung adenocarcinoma","volume":"11","author":"Guibert","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s43856-025-00921-8","article-title":"Detectin of actionable mutatins in circulating tumor DNA for non-small cell lung cancer patients","volume":"5","author":"Rozendal","year":"2025","journal-title":"Commun. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JOP.18.00214","article-title":"Improving timeliness of oncology assessment and cancer treatment through implementation of a multidisciplinary lung cancer clinic","volume":"15","author":"Stone","year":"2021","journal-title":"J. Oncol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.7861\/clinmed.2021-0160","article-title":"The diagnostic pathway in lung cancer patients with best supportive care decisions: Are there lessons to be learnt?","volume":"22","author":"King","year":"2022","journal-title":"Clin. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A.B., and Bleckmann, A. (2023). Liquid Biopsies in Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15051430"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jalm\/jfad105","article-title":"Implementing next-generation sequencing process changes to increase capacity and improve timeliness of molecular biomarker profiling for lung cancer patients","volume":"9","author":"Semenuk","year":"2024","journal-title":"J. Appl. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3348\/kjr.2019.0014","article-title":"Non-diagnostic CT-guided percutaneous needle biopsy of the lung: Predictive factors and final diagnoses","volume":"20","author":"Tongbai","year":"2019","journal-title":"Korean J. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/gcc.22522","article-title":"Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer","volume":"57","author":"Liu","year":"2018","journal-title":"Genes Chromosome Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.lungcan.2018.05.002","article-title":"Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-na\u00efve advanced nonsquamous non-small cell lung cancer patients","volume":"121","author":"Xie","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2325332","DOI":"10.1001\/jamanetworkopen.2023.25332","article-title":"Association of circulating tumor DNA testing before tissue diagnosis with time to treatment amonth patients with suspected advanced lung cancer. The ACCELERATE nonrandomized clinical trial","volume":"6","author":"Law","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100443","DOI":"10.1016\/j.jlb.2025.100443","article-title":"Circulating tumor DNA as part of the routine work-up for patients with suspected advanced lung cancer","volume":"10","author":"Holjak","year":"2025","journal-title":"J. Liq. Biopsy"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:49:08Z","timestamp":1768384148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010042"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010042","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}